Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality
Endocrinology, Diabetes & Metabolism · 2025-05 · 8 (3)
DOI: 10.1002/edm2.70035 ↗At a glance
Journal article in Endocrinology, Diabetes & Metabolism, published online on 2025-03-26. Written by Mahsa Abbaszadeh and 5 co-authors. Institution: Endocrinology and Metabolism Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Major MEDLINE topics: Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease, Fatty Liver. Cited 7 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background and Aims Considering recent revisions in the nomenclature for fatty liver disease, alongside limited data on sex‐specific differences in its cardiovascular/mortality outcomes, this study aims to investigate the prevalence and impact of metabolic‐associated fatty liver disease (MAFLD) on cardiovascular disease (CVD) and mortality in men and women over a 12‐year follow‐up period.
Methods
In this large population‐based cohort study, 7101 individuals aged ≥ 30 were enrolled. The prevalence of MAFLD was investigated in both genders. After excluding individuals with a history of previous CVD, 6331 participants were followed up for CVD and mortality over 12 years. Steatosis was defined as fatty liver index (FLI) ≥ 60. Multivariate‐adjusted hazard ratios (HRs) were calculated for CVD and mortality.
Results
The prevalence of MAFLD was 43.2%, higher in men (46.5%) than women (40.6%). Men with MAFLD (47.7 ± 12.1) were younger than women (52.2 ± 11.1). In the 12‐year follow‐up of 6331 individuals, multivariable‐adjusted CVD HRs for MAFLD were 1.36 (1.10–1.67) in men and 1.48 (1.16–1.88) in women. Adjusted mortality HRs were 1.17 (0.86–1.59) and 1.38 (1.00–1.91) in men and women, respectively. Among patients with MAFLD, a subgroup with diabetes faced the highest hazard for CVD and mortality.
Conclusion
This study found that MAFLD is more common in men at a younger age. Despite the higher prevalence in men, women with MAFLD face a greater risk of cardiovascular events and mortality. Findings highlight the importance of gender‐specific considerations in primary prevention programmes for MAFLD‐related cardiovascular disease and mortality.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Endocrinology and Metabolism Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
- Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran.
- Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID profiles: Mahsa Abbaszadeh, Sahar Karimpour Reyhan
Cite
APA
Abbaszadeh, M., Hosseinpanah, F., Tohidi, M., Karimpour Reyhan, S., Mahdavi, M., & Valizadeh, M. (2025). Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality. Endocrinology, Diabetes & Metabolism, 8(3). https://doi.org/10.1002/edm2.70035
Vancouver
Abbaszadeh M, Hosseinpanah F, Tohidi M, Karimpour Reyhan S, Mahdavi M, Valizadeh M. Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality. Endocrinology, Diabetes & Metabolism. 2025;8(3). doi:10.1002/edm2.70035
BibTeX
@article{Abbaszadeh2025,
author = {Abbaszadeh, Mahsa and Hosseinpanah, Farhad and Tohidi, Maryam and Karimpour Reyhan, Sahar and Mahdavi, Maryam and Valizadeh, Majid},
title = {Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
volume = {8},
number = {3},
doi = {10.1002/edm2.70035}
}
EUVIMED